Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BD114
- Development stage
- Unknown
- Lead developer
- Shanghai BDgene Therapeutics
- Modality
- Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Gene Editing → Gene Therapies, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intraepithelial Injection, Topical (gel Application)
01
Overview
BD114 is an **instantaneous CRISPR/Cas9 gene editing therapy delivered via virus-like particles** designed for the localized treatment of high-grade squamous intraepithelial lesions (HSIL) of the cervix associated with HPV-16 infection. The therapy employs CRISPR/Cas9-mediated genome editing to selectively target and disrupt viral DNA in cervical lesion cells. Developed by Shanghai BDgene Therapeutics, this therapy is being studied for safety, tolerability, and preliminary efficacy. BD114 is delivered either by intraepithelial injection or topical gel application directly to cervical lesions[1][4][6].
- Other names
- CRISPR/Cas9 instantaneous gene editing therapy (BDgene)BD114 virus-like particleBD-114 virus-like particleBD 114 virus-like particleBD 114BD114BD-114
02
Targets
HPV16 DNA (Human papillomavirus type 16 DNA)
Beyond the preview
Go deeper on BD114.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BD114.